HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Aggressive end-of-life care: A disservice to patients
• Should oncology practices be required to publicly report measures of end-of-life care intensity?
• A new love affair — but will you respect me in the morning? Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• DTCandWe: Oncology providers must understand direct-to-consumer testing’s limitations, implications Jill S. Bates, PharmD, MS, BCOP, FASHP
• Despite improvements in bone marrow biopsy, ‘much work to do’ to support APPs, patients Christina Dunbar, MSN, RN, FNP-C, AOCNP
• Sixty years of change at the AJCC keep its ‘language of cancer’ relevant
• Ice chips a ‘no-cost intervention’ to improve oxaliplatin-induced oral symptoms
• Artificial neural network shows potential for assessment of glioblastoma treatment response
• HemOnc Today honors Next Gen Innovators
• Triplet therapy confers benefit among certain patients with advanced breast cancer
• Exercise reduces cancer-related fatigue, boosts muscle strength among patients with breast cancer
• MIW815 plus spartalizumab safe, active among certain patients with advanced breast cancer, melanoma
• FOLFOXIRI-bevacizumab strategy improves survival in unresectable metastatic colorectal cancer
• Medicaid expansion reduces racial disparities in access to timely cancer care
• Olaparib prolongs PFS vs. chemotherapy in BRCA-mutated, platinum-sensitive ovarian cancer
• Neoadjuvant immunotherapy may benefit some patients with oropharynx cancer
• CX-01 with standard induction chemotherapy shows promise among elderly patients with AML
• Smoking associated with poorer-risk cytogenetics, worse survival in acute myeloid leukemia
• Risk score predicts atrial fibrillation with ibrutinib therapy for chronic lymphocytic leukemia
• Isatuximab regimen extends PFS in relapsed, refractory multiple myeloma
• Socioeconomic factors linked to multiple myeloma survival
• Pembrolizumab substantially improves long-term survival in non-small cell lung cancer
• Lurbinectedin induces response in small cell lung cancer
• Proton therapy maintains efficacy, reduces toxicity of radiotherapy for locally advanced cancer
• Population-based genetic testing of newborns could reduce pediatric cancer-associated mortality
• Olaparib shows activity in metastatic castration-resistant prostate cancer with certain genetic alterations
• Phase 3 trial fails to confirm OS benefit of olaratumab in advanced soft tissue sarcoma
• Speaker introductions at major meetings may strengthen gender bias
• Umbralisib yields ‘highly encouraging’ results in marginal zone lymphoma
• Osimertinib plus intermittent selumetinib shows preliminary activity in EGFR-mutated lung cancer
• Tumor mutational burden may guide treatment decisions in metastatic colorectal cancer
• Palliative care at home leads to greater pain relief in patients with cancer
• Donor sex, prior pregnancy not linked to mortality risk among transfusion recipients
• Cytoreductive surgery with chemotherapy often safer than other high-risk oncologic procedures
• FDA approves Keytruda-Inlyta combination for first-line treatment of advanced renal cell carcinoma
• FDA approves Doptelet for chronic immune thrombocytopenia
• FDA grants priority review to darolutamide for prostate cancer subtype
• FDA approves Piqray, first PI3K inhibitor for advanced breast cancer
• Breast cancer surgeon joins UPMC Hillman Cancer Center
• City of Hope appoints hematologists to new roles
• University of Arizona Cancer Center appoints interim director